The Oral Calcilytic Encaleret Decreased the Fractional Excretion of Calcium in Individuals with Post-surgical Hypoparathyroidism: Preliminary Findings from an Ongoing Open-label Phase 2 Study

被引：0
|
作者：
Gafni, Rachel I. [1 ]
Roszko, Kelly L. [1 ]
Li, Xiaobai [2 ]
Ferguson, Elizabeth A. [1 ]
Moore, Casey A. [1 ]
Pozo, Karen A. [1 ]
Ampuero, Kimberly T. [1 ]
Meadows, Rita E. J. [1 ]
Sridhar, Ananth V. [3 ]
Mathew, Arun S. [3 ]
Roberts, Mary Scott [3 ]
Adler, Scott H. [3 ]
Nemeth, Edward F. [4 ]
Collins, Michael T. [1 ]
机构：
[1] Nat Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA
[2] NIH, Biostat & Clin Epidemiol, Clin Ctr, Bethesda, MD USA
[3] Calcilytix Therapeut Inc, San Francisco, CA USA
[4] MetisMedica, Montreal, PQ, Canada
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SUN-LB 591
引用
收藏
页码：360 / 361
页数：2
相关论文
共 50 条
  • [21] Interim Results from the HELIOS Trial: A Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Wolfram Syndrome
    Urano, F.
    Marshall, B.
    Hurst, S.
    Viehoever, A.
    Ahmadi, S.
    Hershey, T.
    Van Stavern, G.
    Bravo, Cruz P.
    Carson, Powers J.
    Erpelding, N.
    Cottrell, K.
    Leinders, M.
    Mehta, L.
    ANNALS OF NEUROLOGY, 2025, 96 : S61 - S62
  • [22] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn's Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S466 - S466
  • [23] LONG-TERM SAFETY AND TOLERABILITY OF ORAL TOFACITINIB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM A PHASE 2 OPEN-LABEL 48-WEEK EXTENSION STUDY
    Panes, Julian
    D'Haens, Geert R.
    Higgins, Peter D.
    Mele, Linda
    Moscariello, Michele
    Chan, Gary
    Wang, Wenjin
    Niezychowski, Wojciech
    Su, Chinyu
    Maller, Eric S.
    GASTROENTEROLOGY, 2017, 152 (05) : S599 - S599
  • [24] Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study
    Panes, Julian
    D'Haens, Geert R.
    Higgins, Peter D. R.
    Mele, Linda
    Moscariello, Michele
    Chan, Gary
    Wang, Wenjin
    Niezychowski, Wojciech
    Su, Chinyu
    Maller, Eric
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (03) : 265 - 276
  • [25] Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study
    Panes, J.
    D'Haens, G. R.
    Higgins, P. D. R.
    Mele, L.
    Moscariello, M.
    Chan, G.
    Wang, W.
    Niezychowski, W.
    Su, C.
    Maller, E.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S18 - S19
  • [26] Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma
    Duvic, Madeleine
    Horwitz, Steven M.
    Kim, Youn H.
    Zinzani, Pier Luigi
    Bhat, Gajanan
    Sharma, Pankaj
    Yancik, Sue
    BLOOD, 2015, 126 (23)
  • [27] Preliminary clinical safety and efficacy results from an open-label Phase 2 study of STA-5326, an oral IL-12/IL-23 inhibitor, in patients with moderate to severe chronic plaque psoriasis
    Gottlieb, A
    Cather, J
    Hamilton, T
    Sherman, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB10 - AB10
  • [28] Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study
    Gisslinger, Heinz
    Kralovics, Robert
    Schoder, Renate
    Gisslinger, Bettina
    Buxhofer-Ausch, Veronika
    Strecker, Karin
    Wolf, Dominik
    Willenbacher, Ella
    Greil, Richard
    Egle, Alexander
    Melchardt, Thomas
    Burgstaller, Sonja
    Tarmann, Frank-Josef
    Wachter, Christoph
    Zahriycick, Olen
    Thaler, Josef
    BLOOD, 2011, 118 (21) : 762 - 762
  • [29] Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
    Sacco, Joseph J.
    Harrington, Kevin Joseph
    Olsson-Brown, Anna
    Chan, Tze Y.
    Nenclares, Pablo
    Leslie, Isla
    Bommareddy, Praveen
    Xie, Ben
    Wolff, Johannes
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma
    Shortt, Jake
    Poligone, Brian
    Ribrag, Vincent
    Zinzani, Pier Luigi
    El-Sharkawi, Dima
    Walewski, Jan
    Prica, Anca
    Wilson, Laksmi
    Souza, Sonia
    Keer, Harold N.
    Taylor, Jason A.
    Marchi, Enrica
    BLOOD, 2022, 140 : 12033 - 12034
12345